

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 888 • August 2020

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Accord Healthcare Inc. and Apotex Inc. that the shortages for Ach-Olmesartan HCTZ 40 mg/12.5 mg Tablet (DIN 02468956) and Apo-Olmesartan/HCTZ 40 mg/12.5 mg Tablet (DIN 02453614) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 21, 2020**. The following grouping was removed from the Critical Supply Product List **August 21, 2020**.

OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE

40 MG / 12.5 MG TABLET

00002468956	ACH-OLMESARTAN HCTZ	AHI	\$ 0.3019
00002443120	ACT OLMESARTAN HCT	APH	\$ 0.3019
00002453614	APO-OLMESARTAN/HCTZ	APX	\$ 0.3019
00002476495	AURO-OLMESARTAN HCTZ	AUR	\$ 0.3019
00002319624	OLMETEC PLUS	MFC	\$ 1.1441

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Lenoltec No.3 Tablet (DIN 00653276) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 24, 2020**. The following grouping was removed from the Critical Supply Product List **August 25, 2020**.

CODEINE PHOSPHATE / ACETAMINOPHEN / CAFFEINE

30 MG / 300 MG / 15 MG TABLET

00000653276	TEVA-LENOLTEC NO.3	TEV	\$ 0.0889
00002163926	TYLENOL NO. 3	JAI	\$ 0.1217

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Imiquimod Pump 5% Topical Cream (DIN 02482983) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 24, 2020**. The following grouping was removed from the Critical Supply Product List **August 25, 2020**.

IMIQUIMOD

50 MG / G TOPICAL CREAM

00002482983	TARO-IMIQUIMOD PUMP	TAR	\$ 43.4350
00002239505	ALDARA P	VCL	\$ 52.9314

continued next page...

... continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Triaderm Regular 0.1% Topical Cream (DIN 00716960) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 28, 2020**. The following grouping was removed from the Critical Supply Product List **August 26, 2020**.

TRIAMCINOLONE ACETONIDE

0.1 % TOPICAL CREAM

00000716960	TRIADERM REGULAR	TAR	\$ 0.1024
00002194058	ARISTOCORT R	VCL	\$ 0.1420

Alberta Blue Cross has been advised by Apotex Inc. and Teva Canada Limited that the shortages of Apo-Sucralfate 1 g Tablet (DIN 02125250) and Teva-Sucralfate 1 g Tablet (DIN 02045702) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 28, 2020**. The following grouping was removed from the Critical Supply Product List **August 28, 2020**.

SUCRALFATE

1 G ORAL TABLET

00002125250	APO-SUCRALFATE	APX	\$ 0.3089
00002045702	TEVA-SUCRALFATE	TEV	\$ 0.3089
00002100622	SULCRATE	AXC	\$ 0.6399

Removal of temporary benefit from the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the shortage of Salinex 0.9% Nasal Solution (Drops) (NPN 80024901) manufactured by Exzell Pharma, Salinex 9 mg/ml Nasal Spray (NPN 80024381) manufactured by Exzell Pharma was added as a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

Exzell Pharma has advised Alberta Blue Cross that the shortage of Salinex 0.9% Nasal Solution (Drops) (NPN 80024901) has been resolved. As a result, Salinex 9 mg/ml Nasal Spray (NPN 80024381) will no longer be considered a temporary benefit for the HSDBS after **September 28, 2020**. These products were removed from the Critical Supply Product List **August 27, 2020**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

